Eli Lilly (https://www.lilly.com/) closed the agreement to acquire AurKa Pharma. This last one was established by TVM Capital Life Science to develop the Aurora kinase A inhibitor AK-01 for oncology indications; the compound was originally discovered at Lilly and represents a potential first-in-class asset, as Aurora kinases are believed to play a crucial role in cellular division by controlling chromosomal segregation. After the completion of phase 1 trials, new studies will seek to determine if the selectivity profile of AK-01 can improve efficacy while limiting toxicity risks to a manageable level.